Linked Life Data

15953192

Source:http://linkedlifedata.com/resource/pubmed/id/15953192

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-6-14
pubmed:abstractText
Conjugates based on N-(2-hydroxypropyl)methacrylamide (HPMA) represent a new generation of antibody-targeted polymeric anticancer drugs with both cytotoxic and immunoprotecting/immunomobilizing activity. 20-90% of mice that are cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukaemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-HPMA conjugate develop a long-lasting memory and systemic antitumour resistance. It is suggested that the main activity of the polymeric drug, directly after application is - due to the high level of the drug - of cytotoxic and cytostatic nature. Thereafter, long-term conjugates persist at low concentration in the circulation, which are capable of mobilizing the defence mechanisms of the host. Until now, seven patients with generalized carcinoma were treated with doxorubicin-HPMA-human-Ig conjugate. Disease stabilization, lasting from 6 to more than 18 months, was recorded.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0300-9475
pubmed:author
pubmed:issnType
Print
pubmed:volume
62 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
100-5
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Induction of systemic antitumour resistance with targeted polymers.
pubmed:affiliation
Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. rihova@biomed.cas.cz
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't